| abstract |
The present invention relates to a novel anticancer compound, particularly to a novel compound used for nuclide activation therapy such as neutron capture therapy. In particular, the present invention relates to the general formula: P- (L-NAT) n, where P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5 to 6000 kDa, and NAT represents a nuclide-activated therapeutic agent. , L represents a binding molecular part capable of binding the polymer to the neutron capture therapeutic agent, and n represents an integer of 1 to 1000). |